Media and Communications

News

Clinical Studies

Friday, August 30, 2013
Teva Reports Top-Line Results from Final Phase III Study of Armodafinil (NUVIGIL®) in Patients with Major Depression Associated with Bipolar I Disorder

JERUSALEM--(BUSINESS WIRE)--Aug. 30, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced top-line results of its final Phase III clinical study for armodafinil (NUVIGIL®) as adjunct therapy in adults with major depression associated with bipolar I disorder. The study reached statistical significance in several important secondary endpoints, such as responder rate and remission. However, it did not reach its primary endpoint --to determine whether armodafinil treatment (150mg per day) is more effective than placebo Read More »

Monday, July 01, 2013
Phase III Data Published in Annals of Neurology Show That a Higher Concentration Dose of Glatiramer Acetate Given Three Times a Week Reduced Annualized Relapse Rates in the Treatment of Relapsing-Remitting Multiple Sclerosis

JERUSALEM--(BUSINESS WIRE)--Jul. 1, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that data from the Glatiramer Acetate Low-frequency Administration (GALA) study, published in the Annals of Neurology, show that a 40mg/ 1mL dose of COPAXONE® (glatiramer acetate injection) administered subcutaneously three times per week significantly reduced relapse rates at 12 months and demonstrated a favorable safety and tolerability profile in patients with relapsing-remitting multiple sclerosis (RRMS). Currently, t Read More »

Wednesday, June 12, 2013
Teva and Active Biotech Report Positive Results from Phase IIa Study of Laquinimod in Active Lupus Nephritis

Laquinimod showed additive effect in improving renal function when combined with the standard of care treatment Results provide rationale for further studies of laquinimod in active lupus nephritis to confirm the safety and efficacy profile observed in this study JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Jun. 12, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today the results of a Phase IIa study of oral laquinimod Read More »

Wednesday, April 17, 2013
Teva Presented New Data from Phase III Clinical Trial of Milprosa™ (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society

Data Reported Comparable Multiple Pregnancy Rates Among Patients Treated with Investigational Milprosa™ and Progesterone Vaginal Gel JERUSALEM--(BUSINESS WIRE)--Apr. 17, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today presented data from a sub-analysis of a Phase III clinical trial of Milprosa™ (progesterone) vaginal ring, an investigational, once-weekly therapy for luteal phase support in women undergoing in vitro fertilization (IVF). The results were presented at the 61st Annual Meeting of the Pacific Coast Rep Read More »

Wednesday, March 06, 2013
First Patient Enrolled in Third Phase III Study of Oral Laquinimod for Relapsing-Remitting Multiple Sclerosis

CONCERTO Study Enrolling Patients Globally to Evaluate Impact of Laquinimod on Disability Progression JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Mar. 6, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today enrollment of the first patient in the CONCERTO study - the third Phase III placebo-controlled study designed to evaluate the efficacy, safety and tolerability of once-daily oral laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS). The Read More »

Monday, March 04, 2013
Phase III Study of Teva’s Milprosa™ (Progesterone) Vaginal Ring Published in Fertility and Sterility

Data Demonstrated Once-Weekly Milprosa™ Provides Similar Pregnancy Rates to Daily 8 Percent Progesterone Vaginal Gel JERUSALEM--(BUSINESS WIRE)--Mar. 4, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the publication of results of the Phase III clinical trial of Milprosa™ (progesterone) vaginal ring in Fertility and Sterility. The study compared the efficacy and safety of once-weekly Milprosa™ to daily 8 percent progesterone vaginal gel for luteal phase support in in vitro fertilization (IVF) and found Read More »

Tuesday, February 05, 2013
Teva Announces First Patient Enrolled in Largest Clinical Study to Date Evaluating AZILECT® for Mild Cognitive Impairment in Parkinson's Disease

JERUSALEM--(BUSINESS WIRE)--Feb. 5, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today enrollment of the first patient in the MODERATO study – a Phase IV clinical study designed to evaluate the effect of AZILECT® (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI). “Cognitive impairment in PD is a major cause of disability and increased care partner burden,” said Robert A. Hauser, M.D., M.B.A., Director, Parkinson's Disease & Movemen Read More »

Wednesday, January 23, 2013
Teva Reports Top-Line Results from Second Phase III Study of Armodafinil (NUVIGIL®) in Patients with Major Depression Associated with Bipolar 1 Disorder

-Following first, positive trial, second trial fails to demonstrate efficacy in meeting primary and secondary endpoints -Teva remains committed to clinical development program with third, ongoing phase III and open-label extension trials JERUSALEM--(BUSINESS WIRE)--Jan. 23, 2013-- Teva Pharmaceutical Industries Ltd. today announced top-line results of its Phase III clinical program for armodafinil (NUVIGIL®) as adjunct therapy in adults with major depression associated with bipolar 1 disorder. While study 3072 demonstr Read More »

Friday, November 09, 2012
Phase III Data for Teva’s QNASL® (beclomethasone dipropionate) Demonstrate Efficacy Profile in Pediatric Patients with Seasonal Allergic Rhinitis

Additional Phase III Data Show Long-Term Ocular Safety Profile and Support Device Functionality and Reliability JERUSALEM--(BUSINESS WIRE)--Nov. 9, 2012-- Teva Pharmaceutical Industries Ltd. announced today additional data from the Phase III clinical program for QNASL® (beclomethasone dipropionate) Nasal Aerosol, highlighting the drug’s efficacy profile in treating children (ages 6-11) with nasal symptoms of seasonal allergic rhinitis (SAR). QNASL® is a nonaqueous, “dry” nasal aerosol corticosteroid currently approved for the Read More »

Monday, October 22, 2012
Phase IIa Laquinimod Trial Results Show Positive Data for Potential Use in Active Crohn's Disease

Newly Presented Data at 20th United European Gastroenterology (UEG) Week Conference Show Significant Impact of Laquinimod on Clinical Remission versus Placebo JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Oct. 22, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the presentation of Phase IIa clinical data for investigational laquinimod in moderate to severe Crohn’s disease (CD). The findings demonstrated that treatment with orally administered laquinimod 0.5 Read More »

​​​